overall survival
Fig 2 · Panel PD-L1_positive_population_Overall_survival
Panel PD-L1_positive_population_Overall_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Zhi Peng, Yanqiao Zhang, Huiting Xu, Yan Yang, Mudan Yang, Mingjun Zhang, Ying Cheng, Xiaobing Chen, Yueyin Pan, Feng Wang, Qingshan Li, Nong Xu, Likun Liu, Kangsheng Gu, Juxiang Xiao, Ruixing Zhang, Qun Zhao, Jian Chen, Lizhu Lin, Yigui Chen, Yanhong Deng, Shirong Cai, Bin Bai, Yiru Wang, Lin Shen
BMJ 392 e086115
OBJECTIVE: To compare camrelizumab plus capecitabine and oxaliplatin followed by camrelizumab plus apatinib (camre+CAPOX followed by camre+apa), CAPOX alone, and camrelizumab plus CAPOX followed by camrelizumab (camre+CAPOX followed by camre) as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma. DESIGN: Randomised, open label, phase 3 study. SETTING: 75 hospitals in China, 13 March 2019 to 16 August 2021. PARTICIPANTS: 885 adults (≥18 years) with previously untreated, human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. INTERVENTIONS: Patients were randomised (2:2:1) to receive camre+CAPOX followed by camre+apa, CAPOX only, or camre+CAPOX followed by camre, stratified by Eastern Cooperative Oncology Group performance status, peritoneal metastasis, and programmed death ligand 1 (PD-L1) combined positive score. Assignment to camre+CAPOX followed by camre was introduced midway through enrolment. MAIN OUTCOME MEASURES: The primary endpoint was overall survival for camre+CAPOX followed by camre+apa versus CAPOX alone in the PD-L1 positive population (combined positive score >1) and the overall population who received at least one dose of study drug. Comparisons of camre+CAPOX followed by camre versus CAPOX alone and of camre+CAPOX followed by camre+apa versus camre+CAPOX-camre were descriptive. Safety was assessed in all patients who received at least one dose of study drug. RESULTS: 352 patients received camre+CAPOX followed by camre+apa, 349 received CAPOX alone, and 177 received camre+CAPOX followed by camre. At the time of data cut off, 454 of 592 (76.7%) deaths had occurred in the PD-L1 positive population and 709 of 878 (80.8%) in the overall population. Overall survival was longer with camre+CAPOX followed by camre+apa than with CAPOX alone in the PD-L1 positive population (median 15.0 v 12.5 months; hazard ratio 0.80 (95% CI 0.65 to 0.98); one sided P=0.02) and in the overall population (median 13.5 v 12.1 months; hazard ratio 0.80 (0.68 to 0.94); one sided P=0.004). Use of camre+CAPOX followed by camre also showed longer overall survival versus CAPOX in the PD-L1 positive population (median 15.3 v 12.5 months; hazard ratio 0.76 (0.58 to 0.97); one sided nominal P=0.01) and overall population (median 14.2 v 12.1 months; hazard ratio 0.80 (0.65 to 0.98); one sided nominal P=0.02). No overall survival benefit was observed with camre+CAPOX followed by camre+apa versus camre+CAPOX followed by camre. Treatment related adverse events of grade ≥3 occurred in 239 of 352 (67.9%) patients in the camre+CAPOX followed by camre+apa group, 158 of 349 (45.3%) in the CAPOX alone group, and 83 of 177 (46.9%) in the camre+CAPOX followed by camre group. CONCLUSIONS: Initial treatment with camrelizumab plus CAPOX followed by camrelizumab based maintenance was associated with longer overall survival than CAPOX alone in human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Exploratory comparisons between the two camrelizumab based regimens showed no additional survival benefit, with higher rates of treatment related adverse events of grade ≥3 and treatment discontinuations when apatinib was added during maintenance. TRIAL REGISTRATION: ClinicalTrials.gov NCT03813784.
2 个 Figure · 8 个 KM 面板
Fig 2 Kaplan-Meier estimates of overall survival and progression-free survival for patients using camre+CAPOX followed by camre+apa versus CAPOX as preferred treatment for gastric or gastro-oesophageal junction adenocarcinoma. Top panel shows PD-L1 positive population, bottom panel shows overall population. Log rank tests and Cox regression models were stratified by Eastern Cooperative Oncology Group performance status (0 v 1), presence versus absence of peritoneal metastasis, and PD-L1 expression status (positive v negative, overall population only). P values are one sided and based on stratified log rank tests. P values for progression-free survival comparisons are nominal. CAPOX=capecitabine and oxaliplatin; camre+CAPOX-camre+apa=camrelizumab plus CAPOX followed by camrelizumab plus apatinib; CI=confidence interval; PD-L1=programmed death ligand 1
Fig 2 · Panel PD-L1_positive_population_Overall_survival
Panel PD-L1_positive_population_Overall_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 2 · Panel PD-L1_positive_population_Progression-free_survival
Panel PD-L1_positive_population_Progression-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 2 · Panel Overall_population_Overall_survival
Panel Overall_population_Overall_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 2 · Panel Overall_population_Progression-free_survival
Panel Overall_population_Progression-free_survival 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 3 Kaplan-Meier estimates of overall survival and progression-free survival for patients using camre+CAPOX followed by camre versus CAPOX. Top panel shows PD-L1 positive population, bottom panel shows overall population. Log rank tests and Cox regression models were stratified by Eastern Cooperative Oncology Group performance status (0 v 1), presence versus absence of peritoneal metastasis, and PD-L1 expression status (positive v negative, overall population only). P values are one sided, derived from stratified log rank tests, and nominal. CAPOX=capecitabine and oxaliplatin; camre+CAPOX followed by camre=camrelizumab plus CAPOX followed by camrelizumab alone; CI=confidence interval; PD-L1=programmed death ligand 1
Fig 3 · Panel PD-L1_positive_population_-_Overall_survival
Panel PD-L1_positive_population_-_Overall_survival 是同一 Fig 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 3 · Panel PD-L1_positive_population_-_Progression-free_survival
Panel PD-L1_positive_population_-_Progression-free_survival 是同一 Fig 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 3 · Panel Overall_population_-_Overall_survival
Panel Overall_population_-_Overall_survival 是同一 Fig 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 3 · Panel Overall_population_-_Progression-free_survival
Panel Overall_population_-_Progression-free_survival 是同一 Fig 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。